

| Patient Information | Specimen Information | Client Information |
|---------------------|----------------------|--------------------|
| | | |

| Cardio IQ® | | | | | | | | | |
|------------------|---------------|-------------|-------------------------|----------|-------|---------------|-------|------------|--|
| Test Name | Current | | Risk/Reference Interval | | | | Units | Historical | |
| | Result & Risk | | Optimal | Moderate | High | Result & Risk | | | |
| | Optimal | Non-Optimal | | | | | | | |
| APOLIPOPROTEINS | | | | | | | | | |
| APOLIPOPROTEIN B | 84 | | <90 | 90-129 | >=130 | mg/dL | | | |

For details on reference ranges please refer to the reference range/comment section of the report.

SPECIMEN:

| Patient Information | Specimen Information | Client Information |
|---------------------|----------------------|--------------------|
| | | |

| Reference Range/Comments | | | | |
|--|----------|-----------|-----------------|-----|
| Analyte Name | In Range | Out Range | Reference Range | Lab |
| APOLIPOPROTEIN B | 84 | | <90 mg/dL | |
| <p>Reference Range <90</p> <p>Risk Category:</p> <p>Optimal <90</p> <p>Moderate 90-129</p> <p>High > or = 130</p> <p>A desirable treatment target may be <80 mg/dL or lower depending on the risk category of the patient including patients on lipid lowering therapies, patients with ASCVD, diabetes with >1 risk factors, Stage 3 or greater CKD with albuminuria, or heterozygous familial hypercholesterolemia. ApoB relative risk category cut points are based on AACE/ACE and ACC/AHA recommendations (Grundy SM, et al. 2019. doi:10.1016/j.jacc.2018.11.002; Handelsman Y, et al. 2020. doi:10.4158/CS-2020-0490).</p> | | | | |

SPECIMEN: